meta|Evidence - COVID-19

Living meta-analysis and evidence synthesis of therapies for COVID-19

results overview
latest studies
standard queries
browse treatments
mapping
NMA
methods

COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention

see more...

click on circles to display study description...

ACTIV-1 infliximab, 0 NCT04593940

infliximab (n=518) vs. placebo (n=519)

randomized controlled trial risk of bias NA

Studied treatment

infliximab

Control treatment

placebo

in addition to the standard of care, which may include remdesivir. About 90% received remdesivir, and about 85% received dexamethasone

Patients

COVID-19 severe or critically

Method

Remark

preliminary results in a press release

powered by vis.js Network